EUVIMEDEUVIMED entdecken
Open Access

IKZF1 PLUS alterations contribute to outcome disparities in Hispanic/Latino children with B‐lymphoblastic leukemia

Alexandra E Kovach iD, Maximilian Wengyn, My H Vu iD, Andrew Doan iD, Gordana Raca, Deepa Bhojwani

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30996 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Alexandra E Kovach und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hematopathology, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Hispanic or Latino, Ikaros Transcription Factor, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Concern Foundation for Cancer Research, and Tri Delta, National Cancer Institute R25, Children's Hospital Los Angeles.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Compared to other ethnicities, Hispanics/Latinos (H/L) have a high incidence of acute lymphoblastic leukemia (ALL), enrichment of unfavorable ALL genetic subtypes, and worse outcomes, even after correcting for socioeconomic factors. We previously demonstrated increased incidence of the high‐risk genetic drivers IKZF1 deletion and IGH::CRLF2 rearrangement in H/L compared to non‐H/L children with B‐ALL. Here in an expanded pediatric cohort, we sought to identify novel genetic drivers and secondary genetic alterations in B‐ALL associated with H/L ethnicity. Procedure Comprehensive clinicopathologic data from patients with B‐ALL treated from 2016 to 2020 were analyzed. Subtype was determined from karyotype, fluorescence in situ hybridization (FISH), chromosome microarray (CMA), and our next‐generation sequencing (NGS) panel (OncoKids). Non‐driver genetic variants were also examined. p ‐Values less than .05 (Fisher's exact test) were considered significant.

Results

Among patients with B‐ALL at diagnosis ( n = 273), H/L patients (189, 69.2%) were older ( p = .018), more likely to present with CNS2 or CNS3 disease ( p = .004), and NCI high‐risk ALL ( p = .014) compared to non‐H/L patients. Higher incidence of IGH::CRLF2 rearrangement (B‐ALL, BCR::ABL1‐like, unfavorable; p = .016) and lower incidence of ETV6::RUNX1 rearrangement (favorable, p = .02) were also associated with H/L ethnicity. Among secondary (non‐subtype‐defining) genetic variants, B‐ALL in H/L was associated with IKFZ1 deletion alone ( p = .001) or with IGH::CRLF2 rearrangement ( p = .003). The IKZF1 PLUS profile ( IKZF1 deletion plus CDKN2A/2B del, PAX5 del, or P2RY8::CRLF2 rearrangement without DUX4 rearrangement) was identified as a novel high‐risk feature enriched in H/L patients ( p = .001).

Conclusions

Our study shows enrichment of high‐risk genetic variants in H/L B‐ALL and raises consideration for novel therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hispanic or LatinoIkaros Transcription FactorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleHumansInfantMaleBiomarkers, TumorFollow-Up StudiesPrognosisSurvival Rate

Stichwörter der Autor:innen

B‐ALLHispanicacute lymphoblastic leukemiaethnicityleukemiapediatric

Substanzen

Biomarkers, TumorIkaros Transcription FactorIKZF1 protein, human

Autor:innen und Institutionen

  • Hematopathology, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.
  • Keck School of Medicine of University of Southern California, Los Angeles, California, USA.
  • Miller School of Medicine of University of Miami, Miami, Florida, USA.
  • Biostatistics Core, The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
  • Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
  • Cytogenomics, Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.

ORCID-Profile: Alexandra E Kovach, My H Vu, Andrew Doan

Förderung

  • Concern Foundation for Cancer Research, and Tri Delta
  • National Cancer Institute R25
  • Children's Hospital Los Angeles
  • NCI NIH HHS
  • Norris Comprehensive Cancer Center in Los Angeles
  • Interdisciplinary Research
  • Children's Hospital Los Angeles (CH/LA) Department of Pathology and Laboratory Medicine (PLM) Translational Research Fund

Zitieren

APA

Kovach, A. E., Wengyn, M., Vu, M. H., Doan, A., Raca, G., & Bhojwani, D. (2024). IKZF1 PLUS alterations contribute to outcome disparities in Hispanic/Latino children with B‐lymphoblastic leukemia. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30996

Vancouver

Kovach AE, Wengyn M, Vu MH, Doan A, Raca G, Bhojwani D. IKZF1 PLUS alterations contribute to outcome disparities in Hispanic/Latino children with B‐lymphoblastic leukemia. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30996

BibTeX
@article{Kovach2024,
  author = {Kovach, Alexandra E and Wengyn, Maximilian and Vu, My H and Doan, Andrew and Raca, Gordana and Bhojwani, Deepa},
  title = {IKZF1 PLUS alterations contribute to outcome disparities in Hispanic/Latino children with B‐lymphoblastic leukemia},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30996}
}
Kostenlos starten →